TY - JOUR
T1 - Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure
T2 - Contemporary Insights
AU - Wan, Siu Hin
AU - Chen, Horng H.
N1 - Funding Information:
Siu-Hin Wan has no relevant conflicts. Horng Chen has grants from the National Institutes of Health, non-financial support from Mayo Clinic, others from Zumbro Discovery, and grants from Scios, Inc., outside the submitted work. In addition, Dr. Chen has a patent Capricor Therapeutics, Anexon, Inc., and UpToDate with royalties paid.
Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/8/25
Y1 - 2015/8/25
N2 - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.
AB - Diastolic dysfunction encompasses both those who are asymptomatic and those who have heart failure symptoms. Preclinical diastolic dysfunction (PDD), defined as diastolic dysfunction with preserved ejection fraction (EF) without the presence of heart failure symptoms, is prevalent and may progress to heart failure with preserved EF (HFpEF). While the causative factors of HFpEF are multifactorial, targeting PDD and its associated comorbidities prior to development of symptoms can reduce development of heart failure. Diabetes, coronary artery disease, hypertension, and renal dysfunction are targets of treatment in those with diastolic dysfunction that may decrease the risk of heart failure development. This review will focus on PDD, its epidemiology, pathophysiology, comorbid conditions, and management that may prevent development of heart failure.
KW - Diastolic dysfunction
KW - Echocardiography
KW - Heart failure epidemiology
KW - Heart failure treatment
KW - Heart failure with preserved ejection fraction
KW - Preclinical diastolic dysfunction
UR - http://www.scopus.com/inward/record.url?scp=84934967513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934967513&partnerID=8YFLogxK
U2 - 10.1007/s12170-015-0466-1
DO - 10.1007/s12170-015-0466-1
M3 - Review article
AN - SCOPUS:84934967513
VL - 9
JO - Current Cardiovascular Risk Reports
JF - Current Cardiovascular Risk Reports
SN - 1932-9520
IS - 8
M1 - 40
ER -